Intimation of US FDA Inspection at Unit-III of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company as OAI.
Submission of notice published in the newspapers.
Intimation of Participation in Investor meeting to be held on June 12, 2026
Intimation of Participation in Investor meeting to be held on June 10, 2026
Submission of press release that is being issued in connection with receipt of final US FDA approval for Tafacitinib tablets 5 mg and 10 mg.
Submission of press release that is being issued by the Company in connection with inauguration of Theranym- Pioneering India's Large Scale Biologics Contract Manufacturing Facility of Theranym Biologics Private Limited, a subsidiary of the Company.
Intimation of investor meeting to be held on June 8, 2026 at Mumbai
Submission of earning calls transcript.
Intimation of Investor meet at Investec US Pharma and Healthcare Bus Tour 7.0 in New Jersey, USA.
Intimation of Participation in Investor meet at BofA 2026 India Conference at Mumbai
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,390.82 | 2,668.76 | 2,692.03 | 2,894.03 | 2,460.09 | 2,824.59 | 2,916.63 | 2,731.99 | 2,848.17 | 2,789.72 | 2,747.28 | 2,786.55 |
| YOY Revenue Growth % | -14.21% | -11.8% | -21.57% | -18.42% | 2.9% | 5.84% | 8.34% | -5.6% | 15.78% | -1.23% | -5.81% | 2% |
| Other Income | 94.88 | 67.08 | 331.13 | 122.97 | 65.32 | 122.66 | 54.26 | 113.98 | 83.77 | 159.52 | 130.15 | 214.09 |
| Total Income | 2,485.70 | 2,735.84 | 3,023.16 | 3,017.00 | 2,525.41 | 2,947.25 | 2,970.89 | 2,845.97 | 2,931.94 | 2,949.24 | 2,877.43 | 3,000.64 |
| Total Expenses + | 2,059.66 | 2,226.06 | 2,335.94 | 2,237.12 | 2,079.17 | 2,223.50 | 2,337.95 | 2,290.45 | 2,181.85 | 2,193.96 | 2,078.15 | 2,124.33 |
| Cost of Materials Consumed | 1,375.26 | 1,518.33 | 1,465.93 | 1,401.56 | 1,318.18 | 1,424.74 | 1,506.59 | 1,360.70 | 1,340.01 | 1,244.16 | 1,402.55 | 1,251.66 |
| Employee Benefit Expense | 236.06 | 247.51 | 248.08 | 248.91 | 259.33 | 265.48 | 265.15 | 273.11 | 282.97 | 294.37 | 291.10 | 292.71 |
| Other Expenses | 357.84 | 369.09 | 401.00 | 464.86 | 405.61 | 428.58 | 474.05 | 424.84 | 375.99 | 403.07 | 379.99 | 401.45 |
| Operating Profit | 331.16 | 442.70 | 356.09 | 656.91 | 380.92 | 601.09 | 578.68 | 441.54 | 666.32 | 595.76 | 669.13 | 662.22 |
| OPM % | 13.9% | 16.6% | 13.2% | 22.7% | 15.5% | 21.3% | 19.8% | 16.2% | 23.4% | 21.4% | 24.4% | 23.8% |
| Profit Before Tax + | 426.04 | 509.78 | 687.22 | 779.88 | 446.24 | 723.75 | 632.94 | 555.52 | 750.09 | 755.28 | 781.90 | 876.31 |
| Tax Expense | 90.09 | 94.04 | 63.44 | 201.21 | 117.20 | 186.22 | 160.89 | 147.35 | 190.96 | 173.91 | 199.83 | 184.08 |
| Tax % | 21.1% | 18.4% | 9.2% | 25.8% | 26.3% | 25.7% | 25.4% | 26.5% | 25.5% | 23% | 25.6% | 21% |
| Profit After Tax | 335.95 | 415.74 | 623.78 | 578.67 | 329.04 | 537.53 | 472.05 | 408.17 | 559.13 | 581.37 | 582.07 | 692.23 |
| EPS (Basic) | 5.74 | 7.10 | 10.65 | 9.88 | 5.62 | 9.21 | 8.13 | 7.03 | 9.63 | 10.01 | 10.02 | 11.92 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 11,171.72 | 10,933.30 | 10,645.64 | 12,792.28 | 11,287.14 | 15,823.68 | 13,266.48 |
| YOY Revenue Growth % | 2.18% | 2.7% | -16.78% | 13.33% | -28.67% | 19.28% | - |
| Other Income | 587.53 | 328.12 | 616.06 | 433.76 | 670.99 | 589.86 | 258.01 |
| Total Income | 11,759.25 | 11,261.42 | 11,261.70 | 13,226.04 | 11,958.13 | 16,413.54 | 13,524.49 |
| Total Expenses + | 8,578.29 | 8,902.97 | 8,858.78 | 11,611.69 | 10,245.94 | 12,220.53 | 10,804.75 |
| Cost of Materials Consumed | 5,238.38 | 5,610.21 | 5,761.08 | 7,247.69 | 5,783.93 | 7,215.73 | 6,747.55 |
| Employee Benefit Expense | 1,161.15 | 1,063.07 | 980.56 | 1,641.88 | 1,600.04 | 1,735.43 | 1,561.47 |
| Other Expenses | 1,560.50 | 1,704.98 | 1,592.79 | 2,548.56 | 2,367.45 | 2,723.62 | 2,495.73 |
| Operating Profit | 2,593.43 | 2,030.33 | 1,786.86 | 1,180.59 | 1,041.20 | 3,603.15 | 2,461.73 |
| OPM % | 23.2% | 18.6% | 16.8% | 9.2% | 9.2% | 22.8% | 18.6% |
| Profit Before Exceptional | 3,180.96 | 2,358.45 | 2,402.92 | 1,614.35 | 1,712.19 | 4,193.01 | 2,377.70 |
| Exceptional Items | -17.38 | 0.00 | 0.00 | 0.00 | -74.71 | 0.00 | 0.00 |
| Profit Before Tax + | 3,163.58 | 2,358.45 | 2,402.92 | 1,614.35 | 1,637.48 | 4,193.01 | 2,377.70 |
| Tax Expense | 748.78 | 611.66 | 448.78 | 383.94 | 182.77 | 1,080.10 | 504.96 |
| Tax % | 23.7% | 25.9% | 18.7% | 23.8% | 11.2% | 25.8% | 21.2% |
| Profit After Tax | 2,414.80 | 1,746.79 | 1,954.14 | 1,230.41 | 1,454.71 | 3,112.91 | 1,872.74 |
| EPS (Basic) | 41.58 | 29.97 | 33.35 | 21.00 | 24.83 | 53.13 | 31.96 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Non-Current Assets + | 21,257.50 | 19,823.66 | 17,914.85 | 15,210.01 | 11,765.84 | 10,811.10 | 0.00 |
| Property, Plant & Equipment | 2,419.93 | 2,185.29 | 2,222.21 | 3,481.88 | 3,560.27 | 4,457.31 | 0.00 |
| Capital Work in Progress | 228.55 | 87.53 | 132.68 | 239.09 | 225.15 | 719.02 | 0.00 |
| Non-Current Investments | 16,836.15 | 15,209.56 | 13,393.43 | 8,221.77 | 6,584.35 | 4,880.87 | 0.00 |
| Goodwill | 91.70 | 91.70 | 91.70 | 91.70 | 6.99 | 6.99 | 0.00 |
| Other Intangible Assets | 32.10 | 59.81 | 105.22 | 113.92 | 18.57 | 7.76 | 0.00 |
| Current Assets + | 8,021.88 | 7,689.40 | 7,239.13 | 9,723.64 | 9,835.11 | 12,377.86 | 0.00 |
| Inventories | 2,360.57 | 2,359.28 | 2,367.60 | 4,125.26 | 3,356.18 | 4,841.38 | 0.00 |
| Trade Receivables | 4,209.68 | 4,195.05 | 3,776.59 | 4,560.26 | 3,973.24 | 5,928.01 | 0.00 |
| Cash and Cash Equivalents | 160.43 | 295.26 | 83.32 | 129.65 | 48.21 | 383.58 | 0.00 |
| Current Investments | 726.20 | 0.01 | 0.01 | 0.01 | 0.01 | 129.04 | 0.00 |
| LIABILITIES & EQUITY | |||||||
| Total Equity | 22,717.69 | 20,534.11 | 19,722.82 | 17,914.17 | 17,117.34 | 15,924.61 | 0.00 |
| Equity Share Capital | 58.08 | 58.08 | 58.59 | 58.59 | 58.59 | 58.59 | 0.00 |
| Other Equity | 22,659.61 | 20,476.03 | 19,664.23 | 17,855.58 | 17,058.75 | 15,866.02 | 0.00 |
| Non-Current Liabilities | 262.34 | 558.45 | 186.42 | 346.13 | 302.64 | 507.80 | 0.00 |
| Current Liabilities | 6,299.35 | 6,420.50 | 5,244.74 | 6,673.35 | 4,180.97 | 6,756.55 | 0.00 |
| Total Liabilities | 6,561.69 | 6,978.95 | 5,431.16 | 7,019.48 | 4,483.61 | 7,264.35 | 0.00 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activities | 2,933.02 | 1,645.79 | 1,714.80 | 1,821.16 | 3,726.71 | 2,994.42 | 0.00 |
| Cash from Investing Activities | -2,024.96 | -2,065.90 | -159.96 | -3,459.68 | -1,613.51 | -2,648.73 | 0.00 |
| Cash from Financing Activities | -1,072.35 | 616.31 | -1,837.03 | 1,719.48 | -2,447.54 | -27.94 | 0.00 |
| Net Increase/Decrease in Cash | -134.83 | 211.94 | -273.81 | 81.44 | -335.37 | 316.24 | 0.00 |